Kymera Therapeutics, Inc. KYMR
111.95
(3.86)
(3.33%)
as of 25 Sep
- Market cap
- $9.7B
- P/E
- 0.0×
Follow KYMR
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(32.09%) | (25.78%) | (27.09%) | (24.15%) | |
| (27.62%) | (22.89%) | (24.35%) | (21.58%) | ||
ROIC |
(46.94%) | (29.80%) | (25.22%) | (26.72%) | |
Return on Tangible Assets |
(58.81%) | (37.46%) | (47.99%) | (42.44%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 69.52 | |
Free Cash Flow per Share |
(2.64) | (2.77) | (2.50) | (2.42) | |
Free Cash Flow |
(230.21) | (234.34) | (244.00) | (237.96) | |
Capital Expenditures |
(2.28) | (1.45) | (1.42) | (1.19) | |
Piotroski F-Score |
2.00 | 4.00 | 4.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(15.68%) | (9.59%) | (11.07%) | (10.76%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 8.71 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
696.38% | 807.34% | 649.77% | 357.68% | |
Selling, General and Administrative Expense of Revenue |
154.53% | 173.90% | 140.40% | 72.15% | |
Share Based Compensation of Revenue |
135.48% | 152.77% | 119.82% | 62.10% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 0.75 | 0.77 | 0.79 | |
Depreciation/Fixed assets |
(0.04) | (0.01) | (0.02) | (0.03) | |
Capex/Depreciation |
1.24 | 2.56 | 1.78 | 1.13 | |
Revenue per Share |
0.50 | 0.46 | 0.53 | 1.07 | |
Operating CF per Share |
(2.61) | (2.76) | (2.49) | (2.41) | |
Capex per Share |
(0.03) | (0.02) | (0.01) | (0.01) | |
Capex to Sales |
0.05 | 0.04 | 0.03 | 0.01 | |
Net Profit Margin |
(674.81%) | (794.04%) | (611.94%) | (285.33%) |
Columns are period end dates